UPDATE: A FDA advisory panel has ruled that Protein Sciences’ insect cell-based flu vaccine requires more safety tests before being made commercially available in the U.S. The panel said the vaccine appeared to be as safe and effective as more traditional egg-based flu vaccines, but there were concerns over a few patients who had adverse responses, according to Bloomberg. The FDA isn’t required to take the panel’s advice, but, considering how concerned the public is over vaccine safety already, it seems unlikely that the agency would go against the ruling. As detailed in the earlier post below, Protein Sciences received $35 million from the U.S. to develop a H1N1 vaccine last June, but the company spent the better part of last summer fighting involuntary bankruptcy.
One company that may have a faster solution is Protein Sciences, a small Connecticut-based vaccine manufacturer that has made a name for itself by specializing in an alternative approach using insect cells. Protein Science’s process involves growing a fragment of the virus
in insect cells, which is faster and produces a higher yield than the
traditional egg method, says Ted Ross, a vaccine researcher at the
University of Pittsburgh familiar with the company’s work. Other groups
have used insect cell lines to develop vaccines, but the technology is
still relatively new, especially when it comes to large-scale
production. “The advantage of using an insect cell line is that it
produces a very high yield of flu protein,” says Ross. On the downside,
though, he notes, it’s unclear whether vaccines produced in insect cells will work as
well in humans as those from eggs or mammalian cells.
And even if the company does remain solvent, the vaccine probably won’t be available to the public until next spring, well after the larger companies release theirs. But the insect cell method of producing vaccines is likely to grow–let’s hope it does so faster than the superbugs these vaccines are fighting.